Next-Generation Imaging

Latest News

FDA approves new indication for Illuccix in metastatic prostate cancer
FDA approves new indication for Illuccix in metastatic prostate cancer

March 16th 2023

The PSMA-PET imaging product is now approved for the selection of patients with metastatic prostate cancer for whom 177Lu-PSMA-617 is indicated.

blurred image of a clinic hallway
PSMA-PET may lead to treatment delays that unintentionally harm patients with prostate cancer

March 8th 2023

Imaging agent 64Cu-SAR-bisPSMA effective in treatment-naive prostate cancer
Imaging agent 64Cu-SAR-bisPSMA effective in treatment-naive prostate cancer

February 24th 2023

Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels
Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels

February 23rd 2023

human kidney cross section
Clear cell RCC imaging agent 89Zr-DFO-girentuximab demonstrates accuracy

February 19th 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.